Redwood Pharma AB (publ) announced that the company has now completed recruitment and the last person has been included in the clinical study for RP501, the company's medical technology self-care product that is being developed for the treatment of dry eyes. The topline results from the study are expected to be presented at the end of the second quarter of 2023. The study evaluates the safety, tolerability and effect of the treatment in people suffering from dry eyes, with or without the use of contact lenses.

The study consists of two groups, without or with contact lenses and patients have been treated for 90 and 30 days, respectively. The study results will be the basis for Redwood Pharma's application for CE marking with a notified body. RP501 is being developed to be an effective over-the-counter artificial tear for the relief of dry eye, a condition that affects more than 300 million people worldwide.

RP501 is based on IntelliGel - a patented and unique formulation that has the consistency of a drop of water when instilled into the eye, where it instantly transforms into a viscous, protective and lubricating film.